MG
VINC

Marex Group’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Marex Group’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,470
Closed -$58.3K – 695
2023
Q4 		$58.3K Buy
+2,470
New +$41.5K ﹤0.01% 519

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group's VINC Position: Q1 2024 in Review

Marex Group sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2024, closing a stake of 2,470 shares — an estimated $58.3K sold.

Marex Group first reported a position in VINC in Q4 2023 and held it in 1 quarter. The position peaked at $58.3K in Q4 2023. 40 funds tracked by Wall St. Rank hold VINC as of Q1 2024.

  • Marex Group reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Marex Group sold 2,470 Vincerx Pharma, Inc. Common Stock shares in Q1 2024, an estimated $58.3K.
  • Marex Group first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Marex Group's Vincerx Pharma, Inc. Common Stock position peaked at $58.3K in Q4 2023.
  • 40 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2024.

Based on Marex Group's 13F filing for Q1 2024, filed 2 Apr 2026.